Investment & Fund Management
The Seroba Life Sciences
Full Credential Description
The Seroba Life Sciences Fund III, which recently announced its first close at EUR 100 million, aims to capitalize on significant investment opportunities within the Irish and European life sciences sector. The fund, supported by Enterprise IrelandÂ’s Seed and Venture Capital Programme, addresses a critical financing gap in the life sciences industry, which is essential for the growth and development of high-potential Irish businesses.
Seroba Life Sciences focuses on product-oriented, innovative early and mid-stage companies in the life sciences sector, particularly in therapeutics and medical devices. The fund is expected to invest up to EUR 10 million per company, with a strategy that includes leading or co-leading investments and taking board seats to support company growth. The first investment from this fund was made in Endotronix Ireland Limited, which is developing the Cordella TM Heart Failure system. This innovative system integrates a cloud-based patient management platform with an implantable sensor, aiming to improve outpatient management of heart failure, a condition affecting over 20 million people globally.
The involvement of the European Investment Fund (EIF) in this initiative is significant, as it enhances access to early-stage funding in Europe, particularly in Ireland, which is recognized as a major hub for life sciences and medtech. The EIF's commitment is expected to facilitate the commercialization of new and innovative healthcare products, thereby contributing to the sector's sustained growth and internationalization.